Literature DB >> 30463070

Serum Myostatin Levels Are Higher in Fitter, More Active, and Non-Frail Long-Term Nursing Home Residents and Increase after a Physical Exercise Intervention.

Haritz Arrieta1, Gotzone Hervás2, Chloe Rezola-Pardo2, Fátima Ruiz-Litago2, Miren Iturburu3, José Javier Yanguas4, Susana María Gil2, Ana Rodriguez-Larrad2, Jon Irazusta2.   

Abstract

BACKGROUND: Myostatin has been proposed as a candidate biomarker for frailty and sarcopenia. However, the relationship of myostatin with these conditions remains inconclusive.
OBJECTIVE: To determine the association of serum myostatin concentration with body composition, physical fitness, physical activity level, and frailty in long-term nursing home residents. We also aimed to ascertain the effect of an exercise program on myostatin levels.
METHODS: We obtained study data on 112 participants from long-term nursing homes. Participants were randomly assigned to a control or an intervention group and performed a 6-month multicomponent exercise program. Serum myostatin levels were analyzed by ELISA. Assessments also included body composition (anthropometry and bioelectrical impedance), physical fitness (Senior Fitness Test), physical activity level (accelerometry), and frailty (Fried frailty criteria, Clinical Frailty Scale, and Tilburg frailty indicator).
RESULTS: The concentration of myostatin at baseline was positively correlated with: a leaner body composition (p < 0.05), and a higher number of steps per day and light and moderate-vigorous physical activity in women (p < 0.005); greater upper and lower limb strength, endurance, and poorer flexibility (p < 0.05) in men; and better performance (less time) in the 8-ft timed up-and-go test in both women (p < 0.01) and men (p < 0.005). We observed higher concentrations of serum myostatin in non-frail than in frail participants (p < 0.05). Additionally, we found that the implemented physical exercise intervention, which was effective to improve physical fitness, increased myostatin concentration in men (p < 0.05) but not in women. The improvements in physical condition were related with increases in serum myostatin only in men (p < 0.05-0.01).
CONCLUSIONS: Higher serum levels of myostatin were found to be associated with better physical fitness. The improvements in physical fitness after the intervention were positively related to increases in myostatin concentrations in men. These results seem to rule out the idea that high serum myostatin levels are indicative of frailty in long-term nursing home residents. However, although the direction of association was opposite to that expected for the function of myostatin, the use of this protein as a biomarker for physical fitness, rather than frailty, merits further study.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Biomarkers; Exercise training; Frailty; Nursing homes

Mesh:

Substances:

Year:  2018        PMID: 30463070     DOI: 10.1159/000494137

Source DB:  PubMed          Journal:  Gerontology        ISSN: 0304-324X            Impact factor:   5.140


  14 in total

1.  Muscle mass change during chemotherapy in children with high-risk neuroblastoma: a retrospective case series of 24 patients.

Authors:  Natsumi Nakamura; Kenji Kishimoto; Toshiaki Ishida; Sayaka Nakamura; Akihiro Tamura; Aiko Kozaki; Atsuro Saito; Daiichiro Hasegawa; Yoshiyuki Kosaka
Journal:  Eur J Pediatr       Date:  2021-05-10       Impact factor: 3.183

2.  Serum Myostatin and IGF-1 as Gender-Specific Biomarkers of Frailty and Low Muscle Mass in Community-Dwelling Older Adults.

Authors:  J Chew; L Tay; J P Lim; B P Leung; A Yeo; S Yew; Y Y Ding; W S Lim
Journal:  J Nutr Health Aging       Date:  2019       Impact factor: 4.075

3.  Implications of maraviroc and/or rapamycin in a mouse model of fragility.

Authors:  Laura Pérez-Martínez; Lourdes Romero; Sandra Muñoz-Galván; Eva M Verdugo-Sivianes; Susana Rubio-Mediavilla; José A Oteo; Amancio Carnero; José-Ramón Blanco
Journal:  Aging (Albany NY)       Date:  2020-04-30       Impact factor: 5.682

Review 4.  Recent advances and future avenues in understanding the role of adipose tissue cross talk in mediating skeletal muscle mass and function with ageing.

Authors:  Andrew Wilhelmsen; Kostas Tsintzas; Simon W Jones
Journal:  Geroscience       Date:  2021-02-02       Impact factor: 7.713

5.  A highly prevalent SINE mutation in the myostatin (MSTN) gene promoter is associated with low circulating myostatin concentration in Thoroughbred racehorses.

Authors:  Victoria O'Hara; Amélie Cowan; Dominique Riddell; Claire Massey; John Martin; Richard J Piercy
Journal:  Sci Rep       Date:  2021-04-12       Impact factor: 4.379

Review 6.  A Vicious Cycle of Osteosarcopeniain Inflammatory Bowel Diseases-Aetiology, Clinical Implications and Therapeutic Perspectives.

Authors:  Dorota Skrzypczak; Alicja Ewa Ratajczak; Aleksandra Szymczak-Tomczak; Agnieszka Dobrowolska; Piotr Eder; Iwona Krela-Kaźmierczak
Journal:  Nutrients       Date:  2021-01-20       Impact factor: 5.717

Review 7.  Deciphering Myostatin's Regulatory, Metabolic, and Developmental Influence in Skeletal Diseases.

Authors:  Catherine L Omosule; Charlotte L Phillips
Journal:  Front Genet       Date:  2021-03-29       Impact factor: 4.599

8.  Low serum klotho concentration is associated with worse cognition, psychological components of frailty, dependence, and falls in nursing home residents.

Authors:  Begoña Sanz; Haritz Arrieta; Chloe Rezola-Pardo; Ainhoa Fernández-Atutxa; Jon Garin-Balerdi; Nagore Arizaga; Ana Rodriguez-Larrad; Jon Irazusta
Journal:  Sci Rep       Date:  2021-04-27       Impact factor: 4.379

9.  Muscle and serum myostatin expression in type 1 diabetes.

Authors:  Athan G Dial; Cynthia M F Monaco; Grace K Grafham; Nadya Romanova; Jeremy A Simpson; Mark A Tarnopolsky; Christopher G R Perry; Evangelia Kalaitzoglou; Thomas J Hawke
Journal:  Physiol Rep       Date:  2020-07

Review 10.  Myostatin as a Biomarker of Muscle Wasting and other Pathologies-State of the Art and Knowledge Gaps.

Authors:  Jan Baczek; Marta Silkiewicz; Zyta Beata Wojszel
Journal:  Nutrients       Date:  2020-08-11       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.